期刊文献+

内皮抑素联合放射治疗对裸鼠Lewis肺癌血管抑制作用的实验研究 被引量:6

Synergistic Inhibitory Effects of Endostatin and Radiation Therapy on Angiogenesis of Lewis Lung Cancer in Nude Mice
下载PDF
导出
摘要 目的探讨内皮抑素联合放射治疗对荷Lewis肺癌小鼠的体内抑瘤效应,分析对肿瘤血管生成的抑制作用。方法32只荷Lewis肺癌的小鼠随机分为对照组、放射治疗组(1Gy/次,14d)、内皮抑素治疗组(10mg/kg,14d)和内皮抑素联合放疗治疗组,观察各组小鼠照射后不同时间肿瘤体积变化,第15天用免疫组化法检测肿瘤组织微血管密度。结果内皮抑素联合放射治疗组小鼠肿瘤体积明显小于对照组、放疗组及内皮抑素治疗组,第15天肿瘤组织微血管密度明显低于放疗组及内皮抑素治疗组。结论内皮抑素联合放射治疗抑瘤效应明显优于单纯放射治疗及内皮抑素治疗组,其机理可能是两者对抗肿瘤血管生成具有协同作用。 Objective To study the synergistic inhibitory effects of endostatin and radiation therapy on tumor growth and angiogenesis of Lewis lung cancer in nude mice. Methods 32 mice bearing Lewis lung cancer were randomly divided into control group, radiation group, endostatin group, and radiation + endostatin group. The tumor growth was observed and the alteration of tumor size was calculated at different time. The tumor microvessel density was determined by immunohistochemistry assay at 15d. Results Compared with the first three groups, the tumor volume of the last group was significantly smaller, and the tumor microvessel density was significantly lower. Conclusion Endostatin combined with radiation has better synergistic inhibitory effects on Lewis lung cancer, and the mechanisms might be correlated with their synergistic effects on anti-angiogenesis.
出处 《实用临床医药杂志》 CAS 2007年第2期8-11,共4页 Journal of Clinical Medicine in Practice
基金 江苏省卫生厅科研指导性课题(Z200504)
关键词 内皮抑素 放射治疗 LEWIS肺癌细胞 endostatin radiation therapy Lewis lung cancer
  • 相关文献

参考文献10

二级参考文献50

  • 1杨林,王金万,汤仲明,刘秀文,黄镜,李树婷,董英,张和平,薛岚,储大同,孙燕.重组人血管内皮抑制素Ⅰ期临床研究[J].中国新药杂志,2004,13(6):548-553. 被引量:154
  • 2周清华,孙燕.加强我国肺癌分子靶向治疗基础和临床研究[J].中国肺癌杂志,2004,7(4):267-269. 被引量:51
  • 3杨林,王金万,崔成旭,黄镜,张和平,李树亭,孙燕.重组人血管内皮抑制素YH-16联合用药治疗晚期非小细胞肺癌的多中心Ⅱ期临床试验[J].中国新药杂志,2005,14(2):204-207. 被引量:116
  • 4[1]O'Reilly MS,Boehm Y,Shing Y,et al.Endostatin:An Endogenous lnhibitor of Angiogenesis and Tumor Growth.Cell,1997,88:277~285
  • 5Folkman J. Role of angiogenesis in tumor growth and metastasis.Semin Oncol,2002,29(6 Suppl 16) : 15-18.
  • 6Huang X, Wong MK, Zhao Q, et al. Soluble recombinant endostatinpurified from Escherichia coli: antiangiogenic activity and antitumor effect. Cancer Res,2001,61(2): 478-481. Erratum in:Cancer Res, 2001,61 ( 15 ) : 5956. Cancer Res, 2001,61 (10) :4297.
  • 7Li B, Wu XY, Zhou H, et al. Acid-induced unfolding mechanism of recombinant human endostatin. Biochemistry, 2004, 43 (9) :2550-2557.
  • 8Eder JP Jr, Supko JG, Clark JW, et al. Phase Ⅰ clinical trial of recombinant human endostatin administered as a short intravenous infusion repeated daily. J Clin Oncol, 2002,20(18) : 3772-3784.
  • 9Kulke M, Bergsland E, Ryan DP, et al. A phase Ⅱ , open-label,safety, pharmacokinetic, and efficacy study of recombinant human endostatin in patients with advanced neuroendocrine tumors. Proc ASCO,2003,22: 958a.
  • 10Scagliotti GV, De Marinis F, Rinaldi M, et al. Phase Ⅲ randomized trial comparing three platinum-based doublets in advanced nonsmall cell lung cancer. J Clin Oncol,2002,20(21) : 4285-4291.

共引文献641

同被引文献44

引证文献6

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部